CAMBRIDGE, MA – January 26, 2016 – Aurora BioPharma, Inc. CEO, Robert Brooks, will present promising CAR T Cell Therapy data in Solid Tumor from FDA Phase I Clinical trials in Glioblastoma and Sarcoma at the 18th Annual BIO CEO & Investor Conference taking place February 8-9, 2016 at The Waldorf Astoria New York. Aurora’s presentation time is as follows:
Event: BIO CEO & Investor Conference
Date: Monday, February 8th
Time: 11:15 am est
Room: Park North
Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy in solid tumors. AU105 is a “living-drug” CAR T agent that has shown safety and efficacy in pre-clinical and human clinical trials. A Phase 1 trial was completed in 16 Glioblastoma patients, AU105 met its endpoints of safety, tumor killing efficacy, and showed promising signals of increased overall survival. Aurora is planning a randomized multi-site Phase II trial of AU105 in Early Diagnosed Glioblastoma, and a Phase I/II trial in Recurrent Glioblastoma with intracranial injection. Osteosarcoma is the most common type of bone cancer in Children and Adolescents, even after radical amputation of a limb and chemotherapy, survival is poor. A Phase 1 trial in 19 Sarcoma patients was completed, AU-105 met its endpoints of safety, with strong signs of tumor killing efficacy. Aurora is planning a Phase II trial of its CAR T Cell therapy AU105 in Osteosarcoma. The Company also has an equity interest in MedVax Technologies, Inc., its p53 DC cancer vaccine MX-225 has completed two FDA Phase II clinical trials, in Small Cell Lung Cancer and Breast Cancer. The Company is planning a combination trial with MX-225 and a PD-1 antibody in lung cancer with a major pharmaceutical company. MX-225 is also in a Phase II combination trial in breast cancer with Indoximod, an IDO inhibitor from NewLink Genetics.
The BIO CEO & Investor Conference is one of the largest investor conferences attracting investment bankers, industry analysts, and biotechnology executives who delve into relevant business models, deal-making, and investment options in the life sciences. This year’s conference features presentations by over 140 leading biotechnology and pharmaceutical companies, as well as nonprofit and venture philanthropy organizations.
Candace Cobos
VP, Business Development & Public Relations
Harvard Square, One Mifflin Place, Suite 400
Cambridge, MA 02138
Tel: (617) 674-7718 - Fax: (617) 674-7701
Ingraham Building, 25 SE 2nd Avenue, Suite 504
Miami, FL 33131
Tel: (305) 371-2301 - Fax: (305) 371-2304
candace.cobos@aurorabiopharma.net - www.aurorabiopharma.net
New Paradigm in Cancer Immunotherapy
Source: Aurora BioPharma, Inc.